The Angiostrongylus Infection Treatment Market was valued at USD 350.00 million in 2025 and is projected to reach USD 628.87 million by 2033, growing at a CAGR of 7.60% from 2026 to 2033. The market is witnessing steady growth driven by increasing incidence of Angiostrongylus infections, rising awareness of foodborne parasitic diseases, and improving diagnostic and treatment capabilities in endemic regions across Asia-Pacific and parts of the Americas.
The growing consumption of raw or undercooked snails, slugs, and contaminated vegetables, combined with expanding global travel and climate-related spread of intermediate hosts, is contributing to higher infection rates. Governments and healthcare systems are strengthening surveillance, early diagnosis, and anti-parasitic treatment protocols, while pharmaceutical advancements in antiparasitic drugs and supportive therapies continue to support market expansion.
